Toyokawa Gouji, Takada Kazuki, Okamoto Tatsuro, Kozuma Yuka, Matsubara Taichi, Haratake Naoki, Akamine Takaki, Takamori Shinkichi, Katsura Masakazu, Shoji Fumihiro, Hamamoto Ryuji, Oda Yoshinao, Maehara Yoshihiko
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Anticancer Res. 2017 Mar;37(3):1393-1401. doi: 10.21873/anticanres.11461.
BACKGROUND/AIM: Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase that is deeply involved in the pathogenesis of lung cancer. We evaluated the metabolic characteristics of non-small cell lung cancer (NSCLC) in patients with and without expression of EZH2 using F-fluorodeoxyglucose positron-emission tomography/ computed tomography (F-FDG PET/CT).
The EZH2 protein expression of 268 patients with resected NSCLC, whose preoperative F-FDG PET/CT information was available, was evaluated by immunohistochemistry with clone 6A10 antibody; cases with Allred score ≥3 were considered positive.
Maximized standard uptake values in cases of EZH2-positive NSCLC and adenocarcinoma were significantly higher in comparison to EZH2-negative cases (p<0.001, and p<0.001, respectively). The expression of EZH2 in NSCLC and adenocarcinoma was associated with significantly poorer survival.
In patients with NSCLC and adenocarcinoma, EZH2 positivity was associated with a high uptake of FDG, suggesting that EZH2 might define metabolically malignant lung cancer.
背景/目的：zeste同源物2增强子（EZH2）是一种组蛋白甲基转移酶，与肺癌的发病机制密切相关。我们使用F-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描（F-FDG PET/CT）评估了有或无EZH2表达的非小细胞肺癌（NSCLC）患者的代谢特征。
通过使用克隆6A10抗体的免疫组织化学方法，对268例接受手术切除的NSCLC患者的EZH2蛋白表达进行评估，这些患者术前有F-FDG PET/CT信息；Allred评分≥3的病例被视为阳性。
与EZH2阴性病例相比，EZH2阳性NSCLC和腺癌病例的最大标准摄取值显著更高（分别为p<0.001和p<0.001）。NSCLC和腺癌中EZH2的表达与显著较差的生存率相关。
在NSCLC和腺癌患者中，EZH2阳性与FDG高摄取相关，提示EZH2可能定义代谢性恶性肺癌。
